First Light Asset Management LLC boosted its stake in shares of AtriCure Inc. (NASDAQ:ATRC) by 21.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,111,740 shares of the medical device company’s stock after acquiring an additional 197,433 shares during the quarter. AtriCure accounts for 4.6% of First Light Asset Management LLC’s portfolio, making the stock its 4th largest position. First Light Asset Management LLC’s holdings in AtriCure were worth $33,174,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in ATRC. BNP Paribas Arbitrage SA increased its holdings in shares of AtriCure by 63,841.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,673 shares of the medical device company’s stock worth $206,000 after acquiring an additional 7,661 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of AtriCure during the 1st quarter valued at $145,000. Rhumbline Advisers lifted its holdings in shares of AtriCure by 3.4% during the 1st quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock valued at $1,306,000 after buying an additional 1,594 shares during the period. Great Lakes Advisors LLC bought a new position in shares of AtriCure during the 1st quarter valued at $206,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of AtriCure by 12.5% during the 1st quarter. New York State Common Retirement Fund now owns 37,000 shares of the medical device company’s stock valued at $991,000 after buying an additional 4,100 shares during the period. Hedge funds and other institutional investors own 88.85% of the company’s stock.
NASDAQ:ATRC opened at $25.61 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.72 and a quick ratio of 3.10. The firm has a market capitalization of $993.16 million, a price-to-earnings ratio of -27.24 and a beta of 0.33. AtriCure Inc. has a one year low of $22.57 and a one year high of $36.49. The business has a fifty day moving average price of $27.46 and a 200-day moving average price of $28.99.
Several equities analysts have recently weighed in on the company. ValuEngine cut AtriCure from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 19th. BidaskClub raised AtriCure from a “sell” rating to a “hold” rating in a report on Thursday. Needham & Company LLC set a $39.00 price target on AtriCure and gave the company a “buy” rating in a report on Monday, August 12th. Zacks Investment Research cut AtriCure from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of AtriCure in a report on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $36.57.
In other news, CEO Michael H. Carrel sold 25,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $32.00, for a total value of $800,000.00. Following the completion of the sale, the chief executive officer now directly owns 661,103 shares in the company, valued at approximately $21,155,296. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Douglas J. Seith sold 48,804 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.63, for a total value of $1,250,846.52. Following the completion of the sale, the chief operating officer now owns 208,281 shares of the company’s stock, valued at $5,338,242.03. The disclosure for this sale can be found here. Insiders sold a total of 75,258 shares of company stock valued at $2,098,829 over the last 90 days. 8.00% of the stock is currently owned by company insiders.
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Featured Article: Marijuana Stocks
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.